{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:17Z","timestamp":1792979897874,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00817-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:48:23Z","timestamp":1762872503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Sutthipun","family":"Suriya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriyaporn","family":"Wanitchakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"817_CR1","doi-asserted-by":"crossref","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):53\u201360. excluded.","DOI":"10.1056\/NEJM199803263381301"},{"issue":"19","key":"817_CR2","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Guti\u00e9rrez F, et al. Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318.","journal-title":"N Engl J Med"},{"issue":"9868","key":"817_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735\u201343.","journal-title":"Lancet"},{"key":"817_CR4","unstructured":"Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013."},{"key":"817_CR5","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021."},{"issue":"2","key":"817_CR6","first-page":"78","volume":"39","author":"M Povar-Echeverr\u00eda","year":"2021","unstructured":"Povar-Echeverr\u00eda M, Comet-Bernad M, Gasso-S\u00e1nchez A, Ger-Buil A, Navarro-Aznarez H, Mart\u00ednez-\u00c1lvarez R, et al. Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice. Enfermedades Infecciosas Y Microbiol Clin (English ed). 2021;39(2):78\u201382.","journal-title":"Enfermedades Infecciosas Y Microbiol Clin (English ed)"},{"key":"817_CR7","doi-asserted-by":"crossref","unstructured":"Wadesango L. Dolutegravir reported adverse drug reactions: A systematic review. University of the Witwatersrand, Johannesburg (South Africa); 2022.","DOI":"10.21203\/rs.3.rs-882616\/v1"},{"key":"817_CR8","doi-asserted-by":"crossref","unstructured":"Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy-a systematic literature review and network meta-analysis. EClinicalMedicine. 2022;48.","DOI":"10.1016\/j.eclinm.2022.101412"},{"key":"817_CR9","doi-asserted-by":"crossref","unstructured":"Zemariam AB, Tadesse YB, Kassaw AT. Prevalence and patterns of adverse drug events among adult patients with human immune virus infection on dolutegravir-based antiretroviral drug regimens in Amhara comprehensive specialized hospitals, Northwest ethiopia: a multicenter retrospective follow-up study. HIV\/AIDS-Research Palliat Care. 2023:271\u20138.","DOI":"10.2147\/HIV.S411948"},{"issue":"1","key":"817_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11481-021-10042-3","volume":"18","author":"LH Rubin","year":"2023","unstructured":"Rubin LH, O\u2019Halloran JA, Williams DW, Li Y, Fitzgerald KC, Dastgheyb R, et al. Integrase inhibitors are associated with neuropsychiatric symptoms in women with HIV. J Neuroimmune Pharmacol. 2023;18(1):1\u20138.","journal-title":"J Neuroimmune Pharmacol"},{"key":"817_CR11","first-page":"1782","volume":"28","author":"A Badat","year":"2022","unstructured":"Badat A, Lowton K. Case study: new onset of neuropsychiatric symptoms following switching to a dolutegravir regimen. South Afr J Psychiatry. 2022;28:1782.","journal-title":"South Afr J Psychiatry"},{"issue":"1","key":"817_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v24i1.1500","volume":"24","author":"G Maartens","year":"2023","unstructured":"Maartens G, Sinxadi P, Venter W. Weight gain on dolutegravir: association is not the same as causation. South Afr J HIV Med. 2023;24(1):1\u20132.","journal-title":"South Afr J HIV Med"},{"issue":"3","key":"817_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2213-8587(19)30026-9","volume":"7","author":"LM Jaacks","year":"2019","unstructured":"Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"817_CR14","volume-title":"Thailand National guidelines on HIV\/AIDS treatment and prevention 2021\/2022","author":"KCK Ruxrungtham","year":"2022","unstructured":"Ruxrungtham KCK, Chetchotisakd P, Chariyalertsak S, Kiertburanakul SPO, et al. Thailand National guidelines on HIV\/AIDS treatment and prevention 2021\/2022. Nonthaburi: Division of AIDS and STIs, Department of Disease Control; 2022."},{"issue":"1","key":"817_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12981-022-00442-7","volume":"19","author":"A Namulindwa","year":"2022","unstructured":"Namulindwa A, Wasswa JH, Muyindike W, Tamukong R, Oloro J. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the immune suppression syndrome clinic of Mbarara regional referral Hospital, uganda: a mixed design study. AIDS Res Therapy. 2022;19(1):18.","journal-title":"AIDS Res Therapy"},{"issue":"1","key":"817_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41598-023-51144-7","volume":"14","author":"A Fimbo","year":"2024","unstructured":"Fimbo A, Mwalwisi YH, Mwamwitwa K, Matiko D, Mfinanga E, Lyimo J, et al. Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in Mainland Tanzania. Sci Rep. 2024;14(1):615.","journal-title":"Sci Rep"},{"key":"817_CR17","unstructured":"Lichterfeld M, Kuritzkes DR. DAIDS-ES ID: 12049."},{"issue":"2","key":"817_CR18","first-page":"142","volume":"88","author":"C Armstrong","year":"2013","unstructured":"Armstrong C. Endocrine society releases guidelines on diagnosis and management of hypertriglyceridemia. Am Family Phys. 2013;88(2):142.","journal-title":"Am Family Phys"},{"issue":"10","key":"817_CR19","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1093\/jac\/dkaa246","volume":"75","author":"B Alejos","year":"2020","unstructured":"Alejos B, Su\u00e1rez-Garc\u00eda I, Rava M, Bautista-Hern\u00e1ndez A, Gutierrez F, Dalmau D, et al. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. J Antimicrob Chemother. 2020;75(10):3004\u201314.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"817_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","volume":"21","author":"S Savinelli","year":"2024","unstructured":"Savinelli S, Newman E, Mallon PW. Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight Changes, Lipids, glucose and bone metabolism. Curr HIV\/AIDS Rep. 2024;21(6):293\u2013308.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"817_CR21","doi-asserted-by":"crossref","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1).","DOI":"10.24875\/AIDSRev.19000023"},{"issue":"1","key":"817_CR22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1021\/acs.joc.0c02318","volume":"86","author":"A Council","year":"2021","unstructured":"Council A. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. J Org Chem. 2021;86(1):693\u2013708.","journal-title":"J Org Chem"},{"issue":"3","key":"817_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40266-022-01003-3","volume":"40","author":"P Sarma","year":"2023","unstructured":"Sarma P, Cassidy R, Corlett S, Katusiime B. Ageing with HIV: medicine optimisation challenges and support needs for older people living with HIV: a systematic review. Drugs Aging. 2023;40(3):179\u2013240.","journal-title":"Drugs Aging"},{"issue":"4","key":"817_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/hiv.13428","volume":"24","author":"J Mwebaza","year":"2023","unstructured":"Mwebaza J, Meya D, Musiime V, Birungi C. Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic. HIV Med. 2023;24(4):491\u2013501.","journal-title":"HIV Med"},{"issue":"2","key":"817_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eimc.2020.02.018","volume":"39","author":"M Povar-Echeverr\u00eda","year":"2021","unstructured":"Povar-Echeverr\u00eda M, Comet-Bernad M, Gasso-S\u00e1nchez A, Ger-Buil A, Navarro-Aznarez H, Mart\u00ednez-\u00c1lvarez R, et al. Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice. Enferm Infecc Microbiol Clin (Engl Ed). 2021;39(2):78\u201382.","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"15","key":"817_CR26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1097\/QAD.0b013e32830007cd","volume":"22","author":"SD Lawn","year":"2008","unstructured":"Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids. 2008;22(15):1897\u2013908.","journal-title":"Aids"},{"issue":"16","key":"817_CR27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1097\/QAD.0b013e3282a4a64d","volume":"21","author":"JN Jarvis","year":"2007","unstructured":"Jarvis JN, Harrison TS. HIV-associated Cryptococcal meningitis. Aids. 2007;21(16):2119\u201329.","journal-title":"Aids"},{"issue":"26","key":"817_CR28","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","volume":"370","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of Cryptococcal meningitis. N Engl J Med. 2014;370(26):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"817_CR29","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.4102\/sajhivmed.v23i1.1452","volume":"23","author":"E Mondleki","year":"2022","unstructured":"Mondleki E, Banda CG, Chandiwana NC, Sokhela S, Wiesner L, Venter F, et al. Effect of obesity on dolutegravir exposure in black Southern African adults living with HIV. South Afr J HIV Med. 2022;23(1):1452.","journal-title":"South Afr J HIV Med"},{"issue":"4","key":"817_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/hiv.13017","volume":"22","author":"WM Han","year":"2021","unstructured":"Han WM, Jiamsakul A, Jantarapakde J, Yunihastuti E, Choi JY, Ditangco R, et al. Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV. HIV Med. 2021;22(4):294\u2013306.","journal-title":"HIV Med"},{"issue":"4","key":"817_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","volume":"75","author":"J Koteff","year":"2013","unstructured":"Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of Iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"817_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of Tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505.","journal-title":"Clin Infect Dis"},{"key":"817_CR33","doi-asserted-by":"crossref","unstructured":"de Pascoa Junior JG, Huntermann R, Viana Gomes VM, de Sousa Marinho Mendes Filho F, Bertozzi JM, Lins PR. Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to Tenofovir Alafenamide fumarate: A systematic review with single arm Meta-analysis. MedRxiv. 2025 Jun 30:2025\u201306.","DOI":"10.1101\/2025.06.29.25330521"},{"key":"817_CR34","doi-asserted-by":"crossref","unstructured":"Lu L, Li X, Liu X, Han Y, Qiu Z, Song X, Li Y, Li X, Cao W, Li T. Comparison of renal function biomarkers of serum creatinine and Cystatin C in HIV-infected people on dolutegravir-containing therapy. Infect Drug Resist. 2022 Jan;1:1695\u2013706.","DOI":"10.2147\/IDR.S347054"},{"issue":"3","key":"817_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/hiv.13391","volume":"24","author":"BJ Aksak-W\u0105s","year":"2023","unstructured":"Aksak-W\u0105s BJ, Kowalska JD, Z\u0105bek P, Serwin K, Rafalska\u2010Kosior M, Go\u0142\u0105b J, Chober D, Skonieczna\u2010\u017bydecka K, Hackiewicz M, Parczewski M. Immune restoration affects 10\u2010year survival in people living with HIV\/AIDS. HIV Med. 2023;24(3):325\u201334.","journal-title":"HIV Med"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00817-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:48:27Z","timestamp":1762872507000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00817-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00817-6","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethical Committee for Human Research at Pakchongnana Hospital, Thailand (Approval No.: ECPC-2566008). Although the study used a retrospective cohort design, all data were obtained exclusively from anonymized patient medical records, with no direct contact or intervention with study participants. Based on the minimal-risk nature of the study and the use of existing data, the Ethics Committee formally waived the requirement for individual informed consent. The study is registered with the Thai Clinical Trials Registry (Registration No.: TCTR20230904001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}